Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The companys product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company was founded in 2012 and is based in Burlingame, California.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Aimed at reducing operating expenses, Kindred Biosciences (KIN) will focus its resources on late-stage assets, prioritizing its IL-31 antibody, IL4 receptor antibody and parvovirus antibody programs, and will cut ~25 employees, including President, COO and co-founder Denise Bevers (she will remain on the board).The actions should trim ~$10M in operating...
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its strategic position. The company will prioritize its most attractive late stage programs and substantially reduce expenses to best position it for success with the previously announced business model.